Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Pulmonology, Respiratory
Pulmatrix, Inc. (NASDAQ: PULM)

Organization & Developments: Pulmatrix

Parents

*Clinical Stage Biotechnology Company Discovering and Developing a New Class of Therapies for the Prevention, Treatment and Control of Respiratory Diseases
*Developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology.
*Pulmatrix is using its technology platform, which it calls iCalm, to create aerosol treatments that attack lung ailments from three directions
*Pulmatrix’s proprietary inhaled cationic airway lining modulators (iCALM) technology was identified as a promising candidate for the development of novel broad spectrum therapeutics for the treatment and prevention of respiratory infections caused by weapo
2010: 110209Pulmatrix Receives $2.2 Million from NIHNIAID to Develop Novel Inhaled Influenza Therapeutics
2010: Pulmatrix Receives $5.7 Million from DARPA (2010)
2011: Pulmatrix Wins $14M to Back Drug For Cystic Fibrosis And Other Lung Ailments (2011)
2020: Pulmatrix, Inc. (NASDAQ:PULM) announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson
Pulmatrix_research.investors.com
Pulmatrix, Inc. Common Stock (PULM) Analyst Research